UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2016-02, Vol.92, p.8-14

2016

Volltextzugriff (PDF)

Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4083-4091

2003

Volltextzugriff (PDF)

Therapieoptionen im Rezidiv des multiplen Myeloms

Der Onkologe, 2010-03, Vol.16 (3), p.282-288

2010

Volltextzugriff (PDF)

420 Analysis of genomic alterations in Ewing sarcoma (German cohort) reveals cooperating mutations and novel therapy targets

European journal of cancer (1990), 2014-11, Vol.50, p.134-134

2014

Volltextzugriff (PDF)

High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2273-2283

2004

Volltextzugriff (PDF)

Stage-adapted Radiation Therapy for Treatment of Localized Gastric Marginal Zone Lymphoma in 326 Patients: Results of the German Study Group on Gastrointestinal Lymphoma (DSGL)

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S72-S72

2012

Volltextzugriff (PDF)

Origins of aberrant DNA methylation in acute myeloid leukemia

Leukemia, 2014-01, Vol.28 (1), p.1-14

2014

Volltextzugriff (PDF)

Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms

Zeitschrift für Herz-, Thorax- und Gefässchirurgie, 2010-04, Vol.24 (2), p.97-104

2010

Volltextzugriff (PDF)

Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2016-03, Vol.51 (3), p.443-445

2016

Volltextzugriff (PDF)

Amsacrine containing induction therapy in elderly AML patients: Comparison to standard induction regimens in a matched-pair analysis

Leukemia research, 2008-03, Vol.32 (3), p.491-494

2008

Volltextzugriff (PDF)

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse

Leukemia, 2015-02, Vol.29 (2), p.377-386

2015

Volltextzugriff (PDF)

563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study

Annals of oncology, 2020-09, Vol.31, p.S485-S485

2020

Volltextzugriff (PDF)

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

Annals of oncology, 2018-04, Vol.29 (4), p.973-978

2018

Volltextzugriff (PDF)

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice

Leukemia, 2012-03, Vol.26 (3), p.465-474

2012

Volltextzugriff (PDF)

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

Leukemia, 2015-05, Vol.29 (5), p.1060-1068

2015

Volltextzugriff (PDF)

An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells

Leukemia, 2016-07, Vol.30 (7), p.1612-1615

2016

Volltextzugriff (PDF)

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

Leukemia, 2016-06, Vol.30 (6), p.1230-1236

2016

Volltextzugriff (PDF)

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Annals of oncology, 2008-05, Vol.19 (5), p.861-870

2008

Volltextzugriff (PDF)

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG

Leukemia, 2009-12, Vol.23 (12), p.2248-2258

2009

Volltextzugriff (PDF)

5-aminolaevulinic acid-induced fluorescence in primary central nervous system lymphoma

World neurosurgery, 2017-02, Vol.98, p.375-380

2017

Volltextzugriff (PDF)

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)

Annals of oncology, 2005-01, Vol.16 (1), p.116-123

2005

Volltextzugriff (PDF)

Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML

Leukemia, 2012-05, Vol.26 (5), p.1030-1037

2012

Volltextzugriff (PDF)

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Annals of oncology, 2017-10, Vol.28 (10), p.2429-2435

2017

Volltextzugriff (PDF)

Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT

Bone marrow transplantation (Basingstoke), 2015-04, Vol.50 (4), p.485-492

2015

Volltextzugriff (PDF)

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients

Annals of oncology, 2012-04, Vol.23 (4), p.990-996

2012

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(95)

Sprache

Englisch
(93)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Humans
(42)
Oncology
(41)
Female
(28)
Middle Aged
(27)
Male
(24)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Adult
(20)
Hematology
(18)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(17)
Medicine
(17)
Medicine & Public Health
(17)
Aged
(16)
Chemotherapy
(15)
Internal Medicine
(15)
Medicine/public Health
(15)
Leukemia
(13)
Antineoplastic Agents
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC

Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group

Therapieoptionen im Rezidiv des multiplen Myeloms

420 Analysis of genomic alterations in Ewing sarcoma (German cohort) reveals cooperating mutations and novel therapy targets

High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial

Stage-adapted Radiation Therapy for Treatment of Localized Gastric Marginal Zone Lymphoma in 326 Patients: Results of the German Study Group on Gastrointestinal Lymphoma (DSGL)

Origins of aberrant DNA methylation in acute myeloid leukemia

Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms

Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation

Amsacrine containing induction therapy in elderly AML patients: Comparison to standard induction regimens in a matched-pair analysis

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse

563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG

5-aminolaevulinic acid-induced fluorescence in primary central nervous system lymphoma

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)

Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients

Suchergebnisse filtern